HTX-011 + Bupivacaine HCl + HTX-011 + HTX-011 + HTX-011
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Analgesia
Conditions
Analgesia
Trial Timeline
Jul 1, 2023 → Dec 1, 2025
NCT ID
NCT03922048About HTX-011 + Bupivacaine HCl + HTX-011 + HTX-011 + HTX-011
HTX-011 + Bupivacaine HCl + HTX-011 + HTX-011 + HTX-011 is a phase 2 stage product being developed by Heron Therapeutics for Analgesia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03922048. Target conditions include Analgesia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03922048 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Analgesia
Other Products from Heron Therapeutics
SUSTOLApproved
77
HTX-011 + Bupivacaine Hydrochloride + Ibuprofen + AcetaminophenApproved
77
Bupivacaine HClApproved
77
HTX-011 + Bupivacaine Hydrochloride + Ibuprofen + AcetaminophenApproved
77
Bupivacaine liposome injectable suspension + Bupivacaine HCl without epinephrine via continuous infusionApproved
77